Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 5/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883069 | 0.87 | MAPT (0.56) | HRH1CYP2C19MAPTKMT2AALDH1A1 | |
| SCHEMBL30557077 | 0.85 | P2RX7 (0.39) | HRH1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL26120675 | 0.85 | P2RX7 (0.39) | HRH1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL4166464 | 0.81 | HTR2A (0.45) | HRH1CYP2C19MAPTKMT2AALDH1A1 | |
| SCHEMBL2880939 | 0.80 | OPRL1 (0.50) | HRH1CYP2C19MAPTKMT2AALDH1A1 | |
| SCHEMBL2877889 | 0.80 | MAPT (0.47) | HRH1CYP2C19MAPTKMT2AALDH1A1 | |
| SCHEMBL27674615 | 0.79 | KDM4E (0.40) | MAPTKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL2882382 | 0.79 | HRH1 (0.43) | HRH1CYP2C19MAPTKMT2AALDH1A1 | |
| SCHEMBL947365 | 0.79 | ALDH1A1 (0.55) | MAPTKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL29683518 | 0.79 | ALDH1A1 (0.55) | MAPTKMT2AALDH1A1MEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4204401-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2023-07-05 | — | — | EP | disclosed |
| CN-116323558-A | Compounds and methods for treating diseases | 艾特里提治疗有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-11603364-B2 | Acyl hydrazone derivative compounds for treating disease | Alterity Therapeutics Limited (AU) | 2023-03-14 | — | — | US | disclosed |
| US-20220064142-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | ADJUVANT BIOTECHNOLOGY PTY LIMITED (AU) | 2022-03-03 | — | — | US | disclosed |
| WO-2022040747-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2022-03-03 | — | — | WO | disclosed |
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603364-B2 | Acyl hydrazone derivative compounds for treating disease | FH, ACOX1, HDAC1 | HRH1 1107/4885CYP2C19 1836/4885MAPT 2903/4885 |
| US-20220064142-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | SLC30A6, SLC39A11, SLC40A1 | HRH1 1792/4885CYP2C19 1708/4885MAPT 2397/4885 |
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | HRH1 2720/4885CYP2C19 3238/4885MAPT 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.